Can-Fite BioPharma (CANF) 6-K Can - Fite Investor Presentation – Fall 2013 Pnina Fishman, PhD CEO

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934

For the Month of October 2013

000-55041
(Commission File Number)

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

 
10 Bareket Street
Kiryat Matalon, P.O. Box 7537
Petach-Tikva 4951778, Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): ____

On October 31, 2013, Can-Fite BioPharma Ltd. (the “Company”) filed in Israel an investor presentation titled “Can-Fite Investor Presentation – Fall 2013” with respect to the Company’s business and uploaded a copy of the same to the Company’s website atwww.canfite.com. A copy of such investor presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit Index

Exhibit No.	Description
99.1	Can-Fite Investor Presentation – Fall 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Can-Fite BioPharma Ltd.
Date:  October 31, 2013	By:	/s/ Motti Farbstein
		Motti Farbstein Chief Operating and Financial Officer